Mycobacteria

Infections by MTC and NTM mycobacteria continue to threaten several million people worldwide while challenging physicians and microbiologists to diagnose and control the spread. Exact species identification requires sophisticated techniques such as molecular diagnostics or mass spectrometry.
The infections resulting from MTC are even more difficult to treat due to intrinsic resistance to antibiotics like penicillin G, sulfonamides, tetracycline, erythromycin, and chloramphenicol.^*不幸的是，非结核分枝杆菌肺部疾病（NTM）的数量在全球范围内稳步增加，随之而来的是NTM中的抗药性数量。因此，识别耐药性模式对于建立成功治疗患者并因此停止抗性菌株的传播至关重要。

^*Jarlier V和Nikaido H（1994）分枝杆菌细胞壁：在自然耐药性抗生素中的作用和作用。FEMS微生物。Lett。123：11–18。

With over 20 years of experience in mycobacteria molecular diagnostics Bruker contributes to the fight against tuberculosis (TB), NTM and leprosy. With the WHO recommendation for our comprehensive portfolio and the only Leprae diagnostic test focusing on resistance in the market our tests are designed to enable laboratories to perform reliable, user-friendly and modern diagnostics in order to heal patients and hinder the further spread of mycobacteria.
Traditional culture methods to identify TB can take up to 4 weeks for a positive result, and even 6-8 weeks for a negative result. Molecular (genetic) testing enables diagnostic labs to achieve the same results for identification for TB and NTM in under 3 hours. This means a significantly faster answer to adequate treatment of patients with a clear understanding of the underlaying resistance patterns.

最近的emergence of advanced mass spectrometry (MS) technology, specifically Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MALDI-TOF) MS, enables clinical microbiology laboratories to master the challenge of mycobacteria identification after cultivation. The unparalleled speed of instruments, such as Bruker’s IVD-CE MALDI Biotyper^®（MBT）除了增强的易用性，高特异性和每次测试成本的显着降低外，系统还将MALDI-TOF MS浮出水是培养物分枝杆菌鉴定的首选技术。